# Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Source: https://onco.cc/trials/nct05601440/  
OnCo record `nct05601440` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lunresertib run by Canadian Cancer Trials Group, now recruiting.

## Summary

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer is a phase 2 interventional study registered as NCT05601440 by Canadian Cancer Trials Group, with 484 participants planned, started 2023-06-13. Conditions recorded: Breast Cancer. Interventions recorded: RP-6306, Gemcitabine, Observation, Niraparib, Fulvestrant, RP-3500, CFI-402257, CFI-400945 and Sacituzumab govitecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05601440
- Phase: 2
- Setting: A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
- Sponsor: Canadian Cancer Trials Group
- Enrolled: 484

## Sources

- ClinicalTrials.gov NCT05601440: https://clinicaltrials.gov/study/NCT05601440

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [CFI-400945](https://onco.cc/drugs/cfi-400945/), [CFI-402257](https://onco.cc/drugs/cfi-402257/), [Lunresertib](https://onco.cc/drugs/lunresertib/)
- companies: [Debiopharm](https://onco.cc/companies/debiopharm/), [Repare Therapeutics](https://onco.cc/companies/repare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05601440.json